Agios Pharmaceuticals Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
540
- Stock Symbol
-
AGIO
- Share Price
-
$27.60
- (As of Friday Closing)
Agios Pharmaceuticals General Information
Description
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Contact Information
Website
www.agios.comCorporate Office
- 88 Sidney Street
- Cambridge, MA 02139-4169
- United States
Corporate Office
- 88 Sidney Street
- Cambridge, MA 02139-4169
- United States
Agios Pharmaceuticals Stock Performance
As of 20-Nov-2026, Agios Pharmaceuticals’s stock price is $27.60. Its current market cap is $1.65B with 59.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $27.60 | $28.77 | $23.00 - $44.09 | $1.65B | 59.8M | 1.05M | -$6.31 |
Agios Pharmaceuticals Financials Summary
As of 30-Sep-2026, Agios Pharmaceuticals has a trailing 12-month revenue of $141M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,398,683 | 678,957 | 930,089 | 672,709 |
| Revenue | 140,843 | 54,028 | 36,498 | 26,823 |
| EBITDA | (410,298) | (464,999) | 675,539 | (378,809) |
| Net Income | (372,898) | (412,781) | 673,725 | (352,088) |
| Total Assets | 1,064,040 | 1,297,225 | 1,663,199 | 937,118 |
| Total Debt | 26,528 | 40,207 | 56,988 | 71,996 |
Agios Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Agios Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Agios Pharmaceuticals Comparisons
Industry
Financing
Details
Agios Pharmaceuticals Competitors (58)
One of Agios Pharmaceuticals’s 58 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| ArriVent Biopharma | Formerly VC-backed | Newtown Square, PA | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Aclaris Therapeutics | Formerly VC-backed | Wayne, PA | ||||
| Olema Oncology | Formerly VC-backed | San Francisco, CA |
Agios Pharmaceuticals Patents
Agios Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026187877-A1 | (pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5h-imidazo[4,5-c]-pyridine derivatives useful for stabilizing phenylalanine hydroxylase mutations | Pending | 05-Mar-2025 | ||
| US-20260274868-A1 | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations | Pending | 05-Mar-2025 | ||
| WO-2026187854-A1 | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations | Pending | 05-Mar-2025 | ||
| WO-2026187855-A1 | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations | Pending | 05-Mar-2025 | ||
| WO-2026187857-A1 | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations | Pending | 05-Mar-2025 | C07D519/00 |
Agios Pharmaceuticals Signals
Agios Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
25.96 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Agios Pharmaceuticals FAQs
-
When was Agios Pharmaceuticals founded?
Agios Pharmaceuticals was founded in 2007.
-
Where is Agios Pharmaceuticals headquartered?
Agios Pharmaceuticals is headquartered in Cambridge, MA.
-
What is the size of Agios Pharmaceuticals?
Agios Pharmaceuticals has 540 total employees.
-
What industry is Agios Pharmaceuticals in?
Agios Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Agios Pharmaceuticals a private or public company?
Agios Pharmaceuticals is a Public company.
-
What is Agios Pharmaceuticals’s stock symbol?
The ticker symbol for Agios Pharmaceuticals is AGIO.
-
What is the current stock price of Agios Pharmaceuticals?
As of 20-Nov-2026 the stock price of Agios Pharmaceuticals is $27.60.
-
What is the current market cap of Agios Pharmaceuticals?
The current market capitalization of Agios Pharmaceuticals is $1.65B.
-
What is Agios Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Agios Pharmaceuticals is $141M.
-
Who are Agios Pharmaceuticals’s competitors?
Ayala Pharmaceuticals, ArriVent Biopharma, Dicerna Pharmaceuticals, Aclaris Therapeutics, and Olema Oncology are some of the 58 competitors of Agios Pharmaceuticals.
-
What is Agios Pharmaceuticals’s annual earnings per share (EPS)?
Agios Pharmaceuticals’s EPS for 12 months was -$6.31.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process